These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33808404)

  • 81. Switching from insulin to dulaglutide therapy in patients with type 2 diabetes: A real-world data study.
    Lee J; Kim HS; Jung CH; Park JY; Lee WJ
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3466. PubMed ID: 33957706
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes.
    Wang R; Wang N; Han Y; Xu J; Xu Z
    ACS Omega; 2021 Mar; 6(12):8271-8278. PubMed ID: 33817486
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
    Makri ES; Makri E; Goulas A; Xanthopoulos K; Polyzos SA
    Ann Gastroenterol; 2024; 37(3):280-290. PubMed ID: 38779641
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Gut microbiota in MAFLD: therapeutic and diagnostic implications.
    Alghamdi W; Mosli M; Alqahtani SA
    Ther Adv Endocrinol Metab; 2024; 15():20420188241242937. PubMed ID: 38628492
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control.
    Youssef ME; Yahya G; Popoviciu MS; Cavalu S; Abd-Eldayem MA; Saber S
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047011
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.
    Shamardl HAMA; Ibrahim NA; Merzeban DH; Elamir AM; Golam RM; Elsayed AM
    Daru; 2023 Jun; 31(1):13-27. PubMed ID: 36991247
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy.
    Khalifa O; H Mroue K; Mall R; Ullah E; S Al-Akl N; Arredouani A
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289914
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota.
    Ni Y; Zheng L; Nan S; Ke L; Fu Z; Jin J
    Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(10):1406-1420. PubMed ID: 36239349
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review.
    Hossain MF; Khan NA; Rahman A; Chowdhury MFI; Bari S; Khan MA; Masud UW; Zakia UB; Paul SP; Tasnim N
    Cureus; 2022 Aug; 14(8):e28367. PubMed ID: 36168335
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Gut microbiota interactions with anti-diabetic medications and pathogenesis of type 2 diabetes mellitus.
    Kant R; Chandra L; Verma V; Nain P; Bello D; Patel S; Ala S; Chandra R; Antony MA
    World J Methodol; 2022 Jul; 12(4):246-257. PubMed ID: 36159100
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).
    Xu X; Poulsen KL; Wu L; Liu S; Miyata T; Song Q; Wei Q; Zhao C; Lin C; Yang J
    Signal Transduct Target Ther; 2022 Aug; 7(1):287. PubMed ID: 35963848
    [TBL] [Abstract][Full Text] [Related]  

  • 92. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
    Androutsakos T; Nasiri-Ansari N; Bakasis AD; Kyrou I; Efstathopoulos E; Randeva HS; Kassi E
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328527
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.
    Yeung MHY; Leung KL; Choi LY; Yoo JS; Yung S; So PK; Wong CM
    Front Pharmacol; 2021; 12():777395. PubMed ID: 35299724
    [TBL] [Abstract][Full Text] [Related]  

  • 94. NASH and Systemic Complications: From Basic to Clinical Research.
    Baumgartner S; Shiri-Sverdlov R
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944726
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.
    Hupa-Breier KL; Dywicki J; Hartleben B; Wellhöner F; Heidrich B; Taubert R; Mederacke YE; Lieber M; Iordanidis K; Manns MP; Wedemeyer H; Hardtke-Wolenski M; Jaeckel E
    Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33808404
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.
    Jojima T; Tomotsune T; Iijima T; Akimoto K; Suzuki K; Aso Y
    Diabetol Metab Syndr; 2016; 8():45. PubMed ID: 27462372
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.
    Park HJ; Han H; Oh EY; Kim SR; Park KH; Lee JH; Park JW
    Sci Rep; 2019 Oct; 9(1):15601. PubMed ID: 31666643
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
    Tahara A; Takasu T
    Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
    [No Abstract]   [Full Text] [Related]  

  • 100. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.